Compare Crispr Therapeutics AG (CRSP) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Crispr Therapeutics AG trades at $54.02 (market cap $5.23B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.6. Which is the better fit depends on your goals.
| CRSP | QDTE | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $76.78 | $36.60 |
52-Week Low | $44.34 | $26.85 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
QDTE trades at $29.80, up 0.51% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The fund faces scrutiny over its high distribution yield, which is reportedly funded by return of capital, leading to net asset value erosion. Recent news highlights underperformance in bull markets and concerns about the sustainability of its weekly payout strategy.
The outlook is cautious due to structural risks in the covered call strategy, with potential for continued NAV decline outweighing the attractive yield. Investors should weigh the income benefits against the risk of capital depletion, as analyst sentiment has turned negative with recent downgrades emphasizing the fund's vulnerability to market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
